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A high incidence of viral persistence and progression to chronic hepatitis are characteristic
features of HCV infection. The aim of this case control study was to investigate the
expression of the apoptosis related proteins Fas (CD95) and Bcl-2 in peripheral blood
mononuclear cells (PBMCs) from patients with chronic HCV and schistosomiasis, and to
evaluate their contribution in the development and maintenance of the different clinical
forms of these diseases. The level of Fas and Bcl-2 expression in PBMCs was detected using
flow cytometry in 85 cases in this study, including chronic HCV (40 patients) and schis-
tosomiasis (25 patients) in addition to 20 healthy controls. Results showed that the
increased apoptotic level correlated with increased Fas expression on the surface of PBMCs
in chronic HCV patients (p ¼ 0.001) which did not show increased expression of the anti-
apoptotic factor Bcl-2 (p ¼ 0.19). Apoptotic PBMCs in intestinal schistosomiasis patients
showed increased expression of Fas (p ¼ 0.001) but again did not exhibit a difference in Bcl-
2 expression (p ¼ 0.61) when compared to either hepatoplenic schistosomiasis or control
patients. The Fas expression was highly significant in HCV > schistosomiasis > control
(p < 0.002) while non-significant difference was found between the 3 groups as regards to
Bcl-2 expression (p > 0.12). It was concluded that the detection of apoptosis of PBMCs in
patients with chronic HCV was associated with increased expression of apoptotic markers
in comparison with schistosomiasis patients, which may be an indicator of disease pro-
gression and severity. Modulation of this process may offer valuable methods of HCV
therapy.
Copyright 2014, Mansoura University. Production and hosting by Elsevier B.V. This is an
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In the immune system, apoptosis appears to play a crucial
role in selection of the T cell repertoire, deletion of self-
reactive T and B lymphocytes, removal of peripheral effector
T cells following termination of an immune response, regu-
lation of immunological memory and in the cytotoxicity of
target cells by cytotoxic lymphocytes (CTLs) and natural killer
(NK) cells [1].
The cell's death is choreographed by a set of previously
dormant proteases, the caspases, which cleave several
hundred cellular substrates [2]. Two principal pathways to
caspase activation have been recognized [3]. One is the death
receptor pathway (extrinsic pathway), which is triggered by
binding of FAS ligand (FASLG) to FAS (CD95) [4]. The second
apoptosis pathway (intrinsic pathway) is induced by mito-
chondria in response to DNA damage, oxidative stress, and
viral proteins [5]. Mitochondrion-dependent apoptosis is
mediated by pro-apoptotic genes (BAX, BAD, BAK, and
others), whereas proteins like BCL-2 and BCL-XL are anti-
apoptotic [6].
Hepatitis C virus (HCV) is a major worldwide causative
pathogen of chronic hepatitis (CHC), liver cirrhosis, and he-
patocellular carcinoma [5]. The fact that HCV exists as an
evolving quasispecies plays an important role in the selection
of escape mutants. Furthermore, several viral proteins inter-
fere with cellular functions, in particular, those involved in
the immune response of the host. Several HCV proteins also
modulate cells through interaction with different effectors
involved in cell proliferation and apoptosis, or in the
interferon-signaling pathway [7]. An accumulating body of
evidence suggests that apoptosis of hepatocytes and periph-
eral blood mononuclear cells (PBMCs) are significantly
involved [8].
In chronic hepatitis C virus (HCV) lymphocytes infiltrating
the liver recognize viral antigens on hepatocytes, become
activated and over-express Fas ligand (FasL) on their surface
[9]. Spontaneous apoptosis of peripheral T cells from HCV-
infected patients was significantly increased compared with
that of normal individuals [9,10].
Apoptosis is an important regulator of host responses
during infection with a variety of parasites [11]. Schistoso-
miasis is a leading tropical disease caused by flatworms of
the genus Schistosoma. It is estimated to affect over 200
million people globally and cause nearly 300,000 deaths
annually [12]. The host granulomatous inflammatory
response to deposited worm eggs leads to hepatic and in-
testinal fibrosis, the major pathological consequences of
infection with the parasitic helminth Schistosoma mansoni.
Schistosomes appear to have evolved several strategies to
down-regulate the host's immune response in order to
promote their own survival [13]. It is well-established that
cells obtained from patients with chronic infection fail to
respond to antigens derived from S. mansoni [14]. Several
lines of evidence suggest that antigens of S. mansoni can
induce apoptosis of host T cells [15].
The aim of this case control study was to assess the
expression of the apoptosis and its related proteins Fas (CD95)
and Bcl-2 in peripheral bloodmononuclear cells from patientswith chronic HCV and schistosomiasis, and to evaluate the
contribution of peripheral blood T cell apoptosis to the
development and maintenance of the different clinical forms
of these diseases.2. Patients and control
This case control study which carried out on 85 cases
attending the clinics of the Tropical Medicine Department at
Mansoura University Hospital. Group I of these cases
comprised 40 chronic HCV patients, which were further sub-
grouped as compensated (n ¼ 22) and decompensated
(n ¼ 18), while group II included 25 patients with schistoso-
miasis, either intestinal (n ¼ 9) or hepatosplenic (n ¼ 16). In
addition, 20 age and sex matched healthy individuals were
also included as control subjects.
Patients infected with other hepatic viruses and/or para-
sites, autoimmune diseases, chronic heart diseases, chronic
renal diseases, malignancy, diabetes mellitus, pregnancy, and
cases with anti-schistosomal therapy (within the last 3 years)
were excluded. All participants were subjected to complete
history taking and thorough clinical examination, and the
required laboratory and radiological investigations were
performed.
Micro-enzyme immunosorbent assay (Axsym; Abbott
Diagnostics-Abbott Max-Planck-Ring2, Wiesbaden, Germany)
was used and confirmed by the detection of circulating HCV
RNA by RT-PCR (PerkineElmer Thermal cycler). Confirmation
of S. mansoni infectionwas carried out through detection of S.
mansoni ova in stool as determined by formol-ether-
concentration technique or rectal snip [16] and indirect
hemagglutination assay (Fumouze Diagnostics-Levallois-
Perret, France). The research protocol was reviewed and
approved by Medical Mansoura University Ethics Committee
for Human Subject Research. The study protocol respected the
most recent declaration of Helsinki, and all patients gave
informed consent before sharing in the study [17].3. Methods
3.1. Lymphocyte separation
Peripheral blood mononuclear cells (PBMCs) were isolated
from heparinized blood by a standard density gradient
centrifugation procedure using Ficoll-Hypaque [18]. Five ml of
heparinized blood were collected in a 15 ml sterile falcon tube
and allowed to stand with an equal volume of dextran/saline
solution for 45 min at 20e25 C. The leukocyte-rich plasma
(buffy coat) was aspirated and centrifuged at 170  g for
10 min. Pellets were then suspended in a volume of PBS
(phosphate-buffered saline) to the starting volume of blood,
placed on top of Ficoll solution and centrifuged at 400  g at
20 C for 40 min. The supernatant was discarded and the
pellets were washed with 0.34 M sucrose to remove platelets.
A few remaining erythrocytes were disrupted by hypotonic
lysis with 10% ammonium chloride (cold 0.2% NaCl for 30 s).
Isolationwas restored by 1.6%NaCl. Lymphocytes were finally
washed and suspended in PBS.
Fig. 1 e (A) lymphocyte apoptosis by Giemsa stain. (B) Lymphocyte apoptosis by acridine orange stain.
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Cells were counted and adjusted to give a final concentration of
2  106 cells/ml in complete RPMI-1640 medium containing
25 mM HEPES buffer (pH 7.3) supplemented with 10% heat-
inactivated fetal calf serum (FCS), 100 U/ml penicillin, and
100mcg/ml streptomycin. The cell suspensionwas divided into
4 aliquots to measure apoptosis at zero time (baseline), then at
24 h, 48 h, and 72 h. Cells were incubated at 37 C in 5% carbon
dioxide. After incubation, the cells were centrifuged (200 g for
5 min at 5 C), then resuspended in ice-cold PBS [18].
3.3. Assessment of cell viability
At time zero and then subsequent times, cells were removed
from culture and counted on a hemocytometer. Cell viability
was determined by trypan blue dyewhich stains only damaged
cells, so the viable cells which exclude the dye were counted.
This method is used to determine the cell concentration (cell
number/ml) in batch cell culture to ensure that optimal level of
growth was reached before routine subculture [18].
3.4. Morphological detection of apoptotic cells
For reliable detection of apoptosis, it is generally recom-
mended to employ at least two different methods togetherwith microscopic verification of the distinctive morphological
alterations. This was done using GrunwaldeGiemsa (Fig. 1A)
and acridine orange stain (Fig. 1B) as well as DNA ladder for
determination of DNA fragmentation by extraction of DNA
followed by gel electrophoresis.
3.4.1. Morphological assessment using Giemsa stain
Cells were removed from culture, fixed in methanol, har-
vested on slides, and stained with May GrunwaldeGeimsa,
then examined by oil immersion light microscope. Five hun-
dred cells were counted per sample and data were reported as
percentage of cells with apoptotic morphology, as assessed
according to the following criteria: cellular condensation
eventually resulting in apoptotic bodies decreases in cell size,
and cytoplasmic vacuolation [19].
3.4.2. Morphological assessment by acridine orange (AO)
stain
One drop of cell suspension was added to one drop of AO so-
lution, mixed gently on a slide, and immediately examined
with Olympus microscope with fluorescence attachment.
Green fluorescence was detected between 500 and 250 nm.
Cells exhibiting bright fluorescent intact or fragmented nuclei
were interpreted as apoptotic cells, whereas viable cells were
interpreted as cells that exhibited a green and diffusely
stained nucleus [20].
Fig. 2 e DNA fragmentation assay using gel electrophoresis. The grading of DNA fragmentation as mild (þ), moderate (þþ),
or severe (þþþ) can be explained by the location of the bands corresponding to the fragmented DNA.
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fragmentation using gel electrophoresis
For extraction of DNA, cells were lysed in lysis buffer, and
incubatedwith proteinase K for 2 h at 55 C andwith RNase for
2 h at 55 C. DNA was precipitated with 2 vol of isopropanol
overnight at 20 C and dissolved in TE buffer. After resus-
pension of pellets in TE buffer, equal amounts were subjected
to electrophoresis, where 2% agarose solutionwas prepared in
TAE buffer. Ethidiumbromidewas added in a concentration of
0.5 mg/ml. DNA was visualized by fluorescence under UV light
[21].
3.4.4. Degree of DNA fragmentation
The grading of DNA fragmentation asmild (þ), moderate (þþ),
or severe (þþþ) can be explained by the location of the bands
corresponding to the fragmented DNA (Fig. 2). In the mild (þ)
degree the location of the bandswas nearer to thewells where
the DNA sample was loaded. In the severe (þþþ) degree the
location of the bands was away from the wells where the DNA
sample was loaded and nearer to the end of the gel. Whereas,
in the in the moderate (þþ) degree the location of the bands
was midway between the wells where the DNA sample was
loaded and the end of the gel. In other wards if the gel was
divided into 3 equal thirds; upper, middle and lower. The (þ)
DNA fragmentation bands were located in the upper third (the
third which contain the wells where DNA samples were
loaded). The (þþ) DNA fragmentation bands were located in
the middle third, and the (þþþ) DNA fragmentation bands
were located in the lower third [22].3.5. Flow cytometry
3.5.1. Flow cytometric measurement of apoptosis via
detection of CD95
Viable lymphocytes were incubated with the unlabeled
monoclonal antibody (MoAb) and a second layer of fluoresceinisothiocyanate (FITC)-conjugated goat anti-mouse immuno-
globulin with heavy chain specificity (Diaclone, UKAS, Cat. no.
853.001.010). All incubations were performed at room tem-
perature, and 2% pooled human AB serum was added to the
buffer throughout all the steps to avoid non-specific binging of
MoAbs to Fc receptors.
The following procedure was done: the lymphocytes were
separated and the cell pellet was suspended in RPMI-1640, and
the cell count was adjusted between 10  106 and 50  106/ml.
The lymphocyte suspension was centrifuged and the super-
natant was discarded, cell pellet resuspended in PBS con-
taining 2% (vol/vol) human AB serum, and the cell count
adjusted between 10  106 and 20  106/ml. Fifty ml of the
lymphocyte suspension (containing from 0.5  106 to
1  106 cells) were added to each Falcon tube. Ten ml of the
MoAb (mouse monoclonal antihuman CD95 antigen FITC-
conjugated) was added, mixed well and incubated for 10 min
at RT. After incubation, the cells were washed 3 times with
PBS containing 2% human antibody (AB) serum and centri-
fuged in between at 200 g for 2min at RT. After the last wash
the supernatant was decanted and the cell pellet resuspended
in PBS and analyzed on the flow cytometer (FAC Scan, Becton
Dickinson). Negative controls were included in the form of
replacement of the AB by an isotopic antibody (IgG2a) or
omitting the use of the AB. The cutoff point of positivity was
considered when more than 20% of the cells stained with a
particular antibody in excess of the background fluorescence
in the negative controls [23].
3.5.2. Flow cytometric measurement of Bcl-2
The procedure was done as previously described for the first 3
steps after which 50 ml of the lymphocyte suspension (con-
taining 0.5  106 to 2  106 cells) were added to each Falcon
tube. Two ml 4% formaldehyde was added to each of the
tubes, which were then incubated for 10 min at RT. The tubes
were then centrifuged and supernatant was discarded, and
the cells were permeabilized with 0.2% Tween 20 (Sigma
Table 1eApoptosis detection by acridine orange and Giemsa stains in the chronic hepatitis C group vs the schistosomiasis
group.
Stain Group Percentage of apoptotic cells P
Mean (±SD)
Acridine orange Chronic hepatitis C (N ¼ 40) 38.71 (±11.74) A*** < 0.001
Schistosomiasis (N ¼ 25) 16.64 (±9.6) B*** < 0.001
Control (N ¼ 20) 7.31 (±1.64) C*** < 0.001
Giemsa Chronic hepatitis C (N ¼ 40) 37.55 (±7.8) A*** < 0.001
Schistosomiasis (N ¼ 25) 15.36 (±8.7) B*** < 0.001
Control (N ¼ 20) 6.9 (±1.33) C*** < 0.001
Student t test, p < 0.001*** extremely significant difference.
p > 0.05 (NS) non-significant difference.
A: chronic HCV vs control.
B: schistosomiasis vs control.
C: chronic HCV vs schistosomiasis.
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resuspended in PBS and 10 ml FITC-conjugated anti-Bcl-2
MoAb (Dako, Carpentaria, California, Cat. no. F 7053) was
added to the tubes which were then incubated for another
25 min and 4 C. The cells were washed twice with PBS,
centrifuged and supernatant discarded, then washed twice
again with PBS. After the last wash, the cell pellet was resus-
pended in 300e500 ml PBS and the sample read on the same
day. Flow cytometry was performed on a FAC scan. Negative
controls included unstained cells only, FITC-IgG1 (Conjugate
control), and FITC-Bcl-2 labeled unstimulated/untreated cells
[23].3.6. Statistical analysis
Statistical analysis was performed using the Statistical Pack-
age for Social Science (SPSS) package program. Quantitative
data were presented as mean and standard deviation. Least
significant difference (LSD) was used to compare quantitative
data between each of two groups. Student t test was used to
compare quantitative data between the two groups, while one
way Anova (F test) was used to compare quantitative data
between more than two groups.
Qualitative data was expressed as number and percentage;
Chi-square test was used as a test of significance for qualita-
tive data between groups. Significancewas consideredwhen pTable 2 e Detection of apoptosis by DNA fragmentation in the
DNA
fragmentation
Chronic
hepatitis C (N ¼ 40)
Sc
() % 0
(þ) % 0
(þþ) % 42.1
(þþþ) % 57.9
Chi-square test, p < 0.01** highly significant difference.
p > 0.001*** extremely significant.
p > 0.05 (NS) non-significant difference.
A: chronic HCV vs control.
B: schistosomiasis vs control.
C: chronic HCV vs schistosomiasis.value was less than 0.05 while non-significance when more
than 0.05. High significance was considered when p value was
less than 0.01 and extreme significance when less than 0.001.4. Results
Comparison of morphological detection of apoptosis between
chronic hepatitis C and schistosomiasis using acridine orange
(Fig. 1B) and Giemsa stains (Fig. 1A) (represented as percentage
of apoptotic cells) showed that the mean level of detection of
apoptotic cells by acridine orange stain was 38.71% vs 16.64%
and by Giemsa stain was 37.55% vs 15.36% in the HCV group
versus (vs) the schistosomiasis group (Table 1), respectively, a
difference that was extremely significant (p < 0.001). Table 2
showed that the degree of DNA fragmentation was (þþþ) in
57.9% of the HCV group while being only (þ) in 52% of schis-
tosomiasis cases, a difference that was also statistically highly
significant (p ¼ 0.02) (Fig. 2).
The increased apoptotic level of peripheral blood mono-
nuclear cells was correlated with increased Fas expression on
the surface of PBMCs in chronic HCV patients (59.39 ± 24.33)
compared to the control group (9.8 ± 1.31, p ¼ 0.001), although
these cells did not show increased expression of the anti-
apoptotic factor Bcl-2 (23.51 ± 10.31) when compared with
controls (20 ± 17.94, p ¼ 0.19). Intestinal schistosomiasischronic hepatitis C group vs the schistosomiasis group.
histosomiasis
(N ¼ 25)
Control
(N ¼ 20)
Test of significance
(chi-square)
0 0 A*** ¼ <0.001
B** ¼ 0.014
C*** ¼ 0.002
52 0
16 6.3
32 12.4
Table 3 e Detection of Fas and Bcl-2 expression by flow cytometry in the chronic hepatitis C group vs the schistosomiasis
group (intestinal and hepatosplenic).
Group Percentage of cells showing positivity P
Mean (±SD)
Fas Chronic HCV (N ¼ 40) 59.39 (±24.33) A***<0.001
B***<0.001
C***<0.001
Schistosomiasis (N ¼ 25)
- Intestinal (9)
- Hepatosplenic (16)
28.20 (±10.72)
46.5 (±14.009)***
25.7 (±5.16)
Control (20) 9.86 (±1.35)
Bcl-2 Chronic HCV (N ¼ 40) 23.51 (±10.31) A* ¼ 0.49
B* ¼ 0.51
C* ¼ 0.12
Schistosomiasis (N ¼ 25)
- Intestinal (9)
- Hepatosplenic (16)
23.65 (±15.17)
21.33 (±34.69)
40.12 (±74.41)
Control (20) 20.33 (±17.84)
Student t test; p > 0.05* (NS) non-significant difference.
p < 0.001*** extremely significant.
A: chronic HCV vs control.
B: schistosomiasis vs control.
C: chronic HCV vs schistosomiasis.
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(46.5 ± 14.009, p ¼ 0.001), but again did not exhibit a difference
in Bcl-2 expression (21.33 ± 34.69, p ¼ 0.61) when compared to
either hepatoplenic patients (25.7 ± 5.16 & 40.12 ± 74.41) or to
the control group (9.8 ± 1.31 & 20 ± 17.94), respectively. How-
ever, Fas expression was highly significant in
HCV > schistosomiasis > control (p < 0.002) while non-Table 4 e Detection of Fas and Bcl-2 expression by flow
cytometry in the chronic hepatitis C (compensated vs non
compensated cases).
Group Fas
Mean (±SD)
Bcl-2
Mean (±SD)
Compensated
HCV (no ¼ 22)
41.4 (±12.88) 22.0 (±3.62)
Decompensated
HCV (no ¼ 18)
64.6 (±12.19) 25.8 (±10.75)
Control
(no ¼ 20
9.86 (±1.35) 20.33 (±17.84)
P p < 0.001 p > 0.05
Fas
Significance
- Compensated vs decompensated
chronic hepatitis C
p***
- Chronic hepatitis C
(compensated) vs control
p***
- Chronic hepatitis C
(decompensated) vs control
p***
Bcl-2
Significance
- Compensated vs decompensated
chronic hepatitis C
p*
- Chronic hepatitis C
(compensated) vs control
p*
- Chronic hepatitis C
(decompensated) vs control
p*
p* > 0.05 (NS) non-significant difference.
p*** < 0.001 extremely significant difference.significant differences were seen between the 3 groups as
regard to Bcl2 expression (p > 0.12), as shown in Table 3.
Detection of Fas expression in compensated and decom-
pensated HCV patients showed extremely significant differ-
ence (p < 0.001) between the compensated patients
(41.4 ± 12.88) vs non decompensated group (64.6 ± 12.19), both
of which were significantly increased when compared with
the control group (9.86 ± 1.35 e P < 0.001), while Bcl2 expres-
sion showed no significant difference between the 3 groups
(22.0 ± 3.62, 25.8 ± 10.75 and 20.33 ± 17.84, respectively;
p > 0.05) as shown in Table 4.5. Discussion
Although few studies have compared apoptosis in patients
with different clinical forms of S. mansoni infection with pa-
tients with chronic hepatitis C virus infection, the present
study showed that the level of apoptosis of peripheral T cells
as detectedmorphologically in patients with chronic hepatitis
was found to be significantly higher than that detected in the
schistosomiasis patients, which may be due to the finding of
significant levels of apoptosis in both compensated and
decompensated cases of chronic hepatitis C [24] but only in
cases of intestinal schistosomiasis, while patients with hep-
atosplenic schistosomiasis showed non-significant apoptosis
of peripheral T cells [14,25].
A high incidence of viral persistence and progression to
chronic hepatitis are characteristic features of HCV infection
[8]. Lymphocytes infiltrating the liver recognize viral antigens
on hepatocytes, become activated and over-express Fas ligand
(FasL) on their surface [9]. Possiblemechanisms by which HCV
increases the sensitivity of T cells to undergo apoptosis
include enhancement of T-cell apoptosis as well as increasing
Fas sensitivity to FasL binding on T cells, ultimately acting to
tip the balance in favor of the virus [10]. This study demon-
strated increased apoptosis of peripheral blood T cells which
was associated with increased surface expression of Fas in
patients with chronic hepatitis C, a finding similar to that
e g y p t i a n j o u rn a l o f b a s i c a n d a p p l i e d s c i e n c e s 1 ( 2 0 1 4 ) 1 3 6e1 4 3142reported by another study which showed that the surface
expression of Faswas significantly high in T cells derived from
patients with chronic hepatitis C [26]. It was found that a close
relationship exists between hepatitis C virus infection of
PBMCs and cell surface Fas expression in patients with hep-
atitis C [27]. The expression of Fas on PBMCs was found to be
significantly increased in these patients, causing apoptotic
cell death. The preferential detection of HCV RNA from Fas-
positive cells, but not from Fas-negative cells, suggests that
HCV infection of PBMCs might induce Fas expression, thus
inducing apoptosis in these Fas-presenting cells, which may
explain the decrease in number of PBMCs observed in patients
with chronic hepatitis C. A progressive increase in its
expression with the severity of liver disease from chronic
hepatitis to cirrhosis was observed in several studies [28].
Significantly increased expression of Fas receptor in PBMCs
were demonstrated in hepatitis C patients with fibrosis and
absent necroinflammation [29], suggesting that Fas receptor
expression may represent a self-limiting mechanism of the
immune response [30], while in hepatitis C patients with
cirrhosis and intense necroinflammation, a decrease in Fas
expression in PBMC's was observed [29].
However, other studies showed that Fas was similarly
expressed on activated T cells of HCV patients compared with
that of healthy individuals [26]. HCV core proteins have been
shown to suppress the immune response of peripheral T
lymphocytes to HCV infection, which has been shown to be
due to increased Fas-mediated apoptosis of cells, contributing
to HCV persistence [31]. It has been demonstrated that the
core protein binds to the cytoplasmic tail of Fas, which may
enhance the downstream signaling event of Fas-mediated
apoptosis. On the other hand, core proteins did not alter the
cell surface expression of Fas, indicating that the increased
sensitivity of core-expressing cells to Fas ligandwas not due to
up-regulation of Fas.
These results suggest that the core protein may promote
the apoptosis of immune cells during HCV infection via the
Fas signaling pathway, thus facilitating HCV persistence [32].
Increased T cell apoptosis observed primarily in the in-
testinal group of schistosomiasis patients was associatedwith
enhanced Fas expression compared with the controls. In-
crease in apoptosis of lymphocytes isolated from S. mansoni-
infected patients in another study supports the hypothesis
that activation-induced cell death (AICD) is potentially a
contributing factor in T helper (Th) cell regulation during
chronic stages of schistosomiasis, which represents a criti-
cally determinant factor in the hosteparasite interaction and
might influence the destiny of parasitic infections either to-
wards establishment of chronic infection or towards host
death [33].
The lack of difference in Bcl-2 expression in peripheral
blood T cells between HCV-infected patients, either compen-
sated or decompensated, and normal controls in our study is
in concordance with several similar findings, including those
who found no significant difference in percentage of Bcl-2 in T
cells among chronic hepatitis C patients and normal subjects
[26], and others who also showed that Bcl-2 expression was
similarly expressed in activated T cells of HCV and normal
individuals [24,34]. The finding that the expression of Bcl-2 is
not increased in the peripheral T cells of patients with chronicHCV infection signifies that Bcl-2 does not exert an anti-
apoptotic effect in HCV-infected patients [35]. Similarly, the
expression of Bcl-2 on peripheral blood T lymphocytes in pa-
tients with intestinal schistosomiasis was not found to be
increased in our study.
However, another study demonstrated that the increased
susceptibility of PBMCs in patients with chronic hepatitis C to
apoptosis was associated with diminished intracellular
expression of the anti-apoptotic protein Bcl-2 [36]. This down-
regulation of Bcl-2 expression may contribute to viral persis-
tence and progression of liver disease in chronic hepatitis C. It
was also shown that signal transducer and activator of Bcl-2
was significantly stimulated in HCV-infected patients [37,38].6. Conclusion
Apoptosis of PBMCs in patients with chronic HCV showed
increased expression of apoptotic markers when compared
with schistosomiasis patients, which may be an indicator of
disease progression and severity. This was due to an increase
in surface receptor expression of pro-apoptotic Fas, associated
with lack of expression of the anti-apoptotic Bcl-2, suggesting
that this factor does not afford protection against apoptosis.
Modulation of apoptotic processes, especially the activation of
the Fas surface receptor, may thus offer valuable methods of
therapy for chronic HCV patients.Acknowledgment
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